JPMorgan Chase & Co. Lowers Adaptive Biotechnologies (NASDAQ:ADPT) Price Target to $19.00

Adaptive Biotechnologies (NASDAQ:ADPT) had its price target decreased by analysts at JPMorgan Chase & Co. from $21.00 to $19.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target points to a potential upside of 31.67% from the company’s previous close.

Other analysts have also recently issued research reports about the company. BTIG Research reaffirmed a “buy” rating and set a $22.00 price target on shares of Adaptive Biotechnologies in a research report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. Piper Sandler set a $21.00 price target on Adaptive Biotechnologies in a research report on Friday, February 6th. TD Cowen lifted their price target on Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Wall Street Zen cut Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

Adaptive Biotechnologies Stock Performance

ADPT stock traded up $0.65 on Wednesday, hitting $14.43. 4,896,838 shares of the company’s stock were exchanged, compared to its average volume of 1,967,962. Adaptive Biotechnologies has a 12-month low of $8.38 and a 12-month high of $20.76. The firm has a 50 day moving average price of $14.32 and a two-hundred day moving average price of $15.92. The stock has a market cap of $2.31 billion, a P/E ratio of -36.07 and a beta of 2.16.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The firm had revenue of $70.87 million for the quarter, compared to the consensus estimate of $61.03 million. During the same period in the previous year, the business earned ($0.20) EPS. The firm’s revenue for the quarter was up 35.1% on a year-over-year basis. Sell-side analysts expect that Adaptive Biotechnologies will post -0.5 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, COO Julie Rubinstein sold 141,583 shares of the business’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $13.29, for a total value of $1,881,638.07. Following the completion of the transaction, the chief operating officer owned 516,610 shares of the company’s stock, valued at $6,865,746.90. The trade was a 21.51% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Sharon Benzeno sold 63,103 shares of the business’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $13.17, for a total value of $831,066.51. Following the completion of the transaction, the insider directly owned 272,751 shares of the company’s stock, valued at approximately $3,592,130.67. This trade represents a 18.79% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 2,417,168 shares of company stock worth $34,153,000. 5.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Adaptive Biotechnologies

Several institutional investors and hedge funds have recently modified their holdings of ADPT. AQR Capital Management LLC lifted its holdings in shares of Adaptive Biotechnologies by 45.8% in the 1st quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock valued at $2,265,000 after buying an additional 97,444 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Adaptive Biotechnologies by 4.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock valued at $511,000 after buying an additional 2,914 shares during the period. Caxton Associates LLP acquired a new position in shares of Adaptive Biotechnologies in the 1st quarter valued at about $93,000. New York State Common Retirement Fund increased its stake in shares of Adaptive Biotechnologies by 39.2% in the 2nd quarter. New York State Common Retirement Fund now owns 47,258 shares of the company’s stock valued at $551,000 after purchasing an additional 13,300 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its stake in shares of Adaptive Biotechnologies by 728.8% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 379,120 shares of the company’s stock valued at $4,417,000 after purchasing an additional 333,379 shares in the last quarter. Institutional investors and hedge funds own 99.17% of the company’s stock.

Key Stories Impacting Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Q1 results beat consensus — Adaptive reported EPS of ($0.13) vs. ($0.16) expected and revenue of $70.87M (up ~35% YoY), a clear topline beat that supports commercial traction and drove investor optimism. GlobeNewswire Q1 Results
• Positive Sentiment: Broker support lifted sentiment — Guggenheim reaffirmed a Buy with a $21 PT and BTIG reiterated Buy with a $22 PT, both implying ~45–53% upside from current levels and reinforcing the bullish case after the print. Benzinga (analyst notes)
• Neutral Sentiment: Management commentary and call transcripts available — Earnings call transcripts (Seeking Alpha / InsiderMonkey) detail management’s take on MRD adoption across clinical testing and drug development, useful for judging durability of revenue growth but not an immediate valuation changer. Seeking Alpha Transcript
• Neutral Sentiment: Analyst write-ups and metric reviews — Coverage from Zacks and MarketBeat breaks down key metrics vs. estimates (revenue beat, margin dynamics) and provides context; these help investors but don’t change the fundamental profitability picture. Zacks analysis
• Negative Sentiment: Still unprofitable with negative margins and ROE — Despite revenue growth, Adaptive reported a negative net margin (~21%) and negative return on equity (~46.7%); sell-side consensus still models a full-year loss (around -$0.50 EPS), which caps near-term valuation expansion until consistent profitability or stronger growth visibility emerges. MarketBeat earnings summary

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.